An Open-label, Multicenter Phase 1 Study to Characterize the Safety, Tolerability, Preliminary Antileukemic Activity, Pharmacokinetics, and Maximum Tolerated Dose or Pharmacological Active Dose of BAY2402234 in Patients With Advanced Myeloid Malignancies
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs BAY 2402234 (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 16 Jul 2018 Planned End Date changed from 25 Sep 2020 to 14 Aug 2020.
- 16 Jul 2018 Planned primary completion date changed from 25 Sep 2020 to 14 Aug 2020.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.